glp-1 heart muscle Frontiers Cardiovascular benefits of glucagon-like peptide-1

Large clinical trials and post-marketing surveillance have not identified increased venous thromboembolism risk, and regulatory bodies have not issued warnings regarding thrombotic events as a class effect

The presence of major pharmaceutical companies such as Novo Nordisk, Pfizer, and Eli Lilly drives innovation and extensive clinical trials, ensuring a robust pipeline of anti-obesity therapies

A liver biopsy is only required if the clinical signs and non-invasive tests do not confirm diagnosis of WD[2]

Liposomal Glutathione: The Mighty Micronaut The second member of our dynamic duo, Liposomal Glutathione, takes a different approach to tackle the bioavailability conundrum